Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright also issued estimates for Prelude Therapeutics’ Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) […]
HC Wainwright restated their buy rating on shares of Prelude Therapeutics (NASDAQ:PRLD – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright also issued estimates for Prelude Therapeutics’ Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.48) […]